Cardiology

Stage IV

Questions discussed in this category

What is the rate of a cardiac events that you quote to a patient with preexisting heart disease going on trastuzumab for metastatic Her2+ breast cancer?

How does it vary for patients with a history of hypertension, diabetes, CHF, and coronary artery disease?

1 Answer available

How do you minimize the risk of cardiotoxicity in metastatic Her2 + breast cancer patients who are receiving trastuzumab and have a history of pre-existing cardiac disease?

1 Answer available

Papers discussed in this category

Cochrane Database Syst Rev, 2008 Apr 16

Cardioprotective interventions for cancer patients receiving anthracyclines.

Eur. J. Cancer, 2013 May 22

Role of cardioprotective therapy for prevention of cardiotoxicity with chemotherapy: a systematic review and meta-analysis.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2006-09-01

Long-term cardiac tolerability of trastuzumab in metastatic breast cancer: the M.D. Anderson Cancer Center experience.

Related Topics in Cardiology